English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Where Psychedelic Medicine Is Headed: Five Predictions Worth Knowing
The psychedelics conversation has shifted. A few years ago, asking a doctor about psilocybin would have earned you a raised eyebrow and maybe a referral. Now there are publicly traded psychedelic companies, billion-dollar valuations, FDA breakthrough designations, and state-level legalization rolling out in real time. If you’re someone weighing a retreat — quietly wondering whether ayahuasca, psilocybin, or another master plant might help with the depression, addiction, or stuck pattern you can’t seem to shake — the ground under you is moving fast. So where is all of this actually going? I’ve been tracking the industry, sitting in ceremonies, and talking to facilitators and investors for years now. A handful of clear themes keep surfacing — and they matter, because they shape what kind of psychedelic healing will be available to you in three years, five years, ten. Here’s an honest read on what’s coming. There are two psychedelic worlds running in parallel right now, and they barely speak. One is the clinical pipeline — pharma companies, FDA trials, standardized dosing, therapists in carpeted offices. The other is everything else: the Shipibo curanderos in the Peruvian Amazon, the underground guides in Brooklyn apartments, the Bwiti iboga practitioners in Gabon, the decriminalization activists in Denver and Oakland. One side has the data and the money. The other side has thousands of years of accumulated practice and, frankly, most of the wisdom about how these substances actually work on a human soul. Several leaders in the field have pointed out — correctly, in my view — that the wall between these worlds is doing nobody any favors. The medical track could learn enormous amounts from traditional preparation, dieta, and integration. The underground could benefit from rigorous safety standards and harm reduction data. What I think we’ll see over the next five years is messy convergence. Not a clean merger — these worlds are too different — but more cross-pollination. More retreats hiring licensed therapists. More clinics borrowing ceremony elements. And more honesty from both sides about what the other does well. For the past few years, venture funding in psychedelics has been overwhelmingly aimed at drug development — new molecules, new patents, new delivery mechanisms. That’s starting to shift. Several investors I respect have been saying the next wave of capital will go into the boring-but-essential stuff: clinics, training programs, integration platforms, insurance pathways. Here’s why that matters to you. Even if the FDA approves psilocybin-assisted therapy for depression tomorrow, you can’t use it unless there are trained therapists in your city, a clinic that takes your insurance, and an aftercare program that doesn’t cost your monthly rent. The molecule is the easy part. The system around the molecule is the hard part. The bottleneck nobody talks about enough is the human one. By some estimates, the field needs tens of thousands of trained psychedelic therapists this decade just to meet projected demand for MDMA and psilocybin treatment. We’re not close. A retreat you book in 2026 — even at a reputable center — may still have facilitators who learned through apprenticeship rather than any formal credential. That’s not necessarily bad. Traditional lineages have trained people brilliantly for centuries. But it does mean you have to do your homework. This is the question I get asked most often, and there’s no single answer. But there are filters worth applying before you wire money to anywhere. The good news: the marketplace is maturing. Five years ago, you mostly had to ask around in person to find a reputable place. Now there’s real comparison, real reviews, real accountability. Drug development is brutal. Most biotech companies that start clinical trials never make it to market, and there’s no reason to expect psychedelics to defy that math. Over the next few years, plenty of well-funded, well-publicized psychedelic startups are going to quietly disappear. Some will fold their programs. Some will pivot. A few will get acquired. This will look, in headlines, like the field collapsing. It isn’t. It’s the normal washout that happens in any new industry — a clearing of the field that leaves behind the operators who actually have something durable. The companies that survive will likely be the ones who took preparation, set, setting, and integration seriously rather than treating psychedelics as just another pill. For you as a potential retreat-goer, this matters less than it sounds. The retreats themselves — especially the established ones in Peru, Costa Rica, the Netherlands, Mexico, Jamaica — operate largely outside this corporate churn. Traditional plant medicine has been running for a long time without any quarterly earnings calls. The cultural shift is real. Ten years ago, telling your boss you were taking a week off for an ayahuasca retreat would have been career-limiting. Today, in plenty of industries — tech, creative work, healthcare ironically enough — it’s become almost mundane. Therapists are getting trained. Veterans’ groups are openly advocating for MDMA-assisted therapy. Athletes and executives talk about plant medicine on podcasts. But don’t mistake the cultural shift for the legal one. Ayahuasca is still federally illegal in the United States outside of religious exemptions. Psilocybin remains Schedule I almost everywhere. Oregon and Colorado are early experiments, not the national norm. Most people who want to work with these medicines still have to either leave the country or operate in legal gray zones at home. What’s changing is the texture of the conversation. People are less embarrassed. Doctors are more curious. The phrase “plant medicine” has stopped sounding fringe to anyone under fifty. That cultural permission slip is part of why retreats are filling up — and part of why the quality of what’s on offer has gotten much better. Demand creates options. If you’re reading this because you’re considering a retreat — for addiction, for depression, for trauma, for the sense that something in your life is asking to be looked at — here’s the honest framing. The industry is professionalizing, but it isn’t finished. The science is encouraging, but it isn’t settled. The legal landscape is opening, but slowly and unevenly. Some retreats are excellent. Some are not. The work itself, when it lands, can be genuinely life-rearranging, but it isn’t magic and it isn’t guaranteed. What I can say with confidence: people who do this carefully — with proper screening, a reputable facilitator, real integration support, and clear intentions — tend to come back changed in ways that hold up over years, not weeks. People who treat it like a vacation or a bucket-list item tend to get a vacation. The variable that matters most isn’t the medicine. It’s how seriously you take the container around it. If any of this has landed somewhere in you, the next move isn’t booking — it’s researching. Read the published trial data. Talk to people who’ve sat in ceremony at the place you’re considering. Ask hard questions and notice how the retreat answers them. When you’re ready to compare specific options, a curated selection of vetted psychedelic and plant-medicine retreats can be browsed on our marketplace here. Take your time. The medicines aren’t going anywhere, and the right retreat is worth waiting for.
Microdosing Psychedelics: An Honest Look at What the Research Actually Shows
A friend once told me she'd been microdosing psilocybin for six weeks and felt like the volume knob on her anxiety had been turned down by about a third. Not silenced. Just turned down. That's the kind of report you hear constantly in this corner of the psychedelic world — quiet, modest, hard to verify, and oddly compelling. Microdosing psychedelics has moved from Silicon Valley curiosity to mainstream conversation over the past few years, and the questions I get from readers researching plant medicine almost always include some version of: should I try this before committing to a full ceremony? Fair question. Let's get into what microdosing actually is, what the science says, and what it doesn't. A microdose is what researchers politely call a sub-perceptual dose — small enough that you don't feel high, don't see walls breathing, don't have any of the textbook psychedelic experiences. You can drive. You can answer emails. You can sit through a meeting without anyone suspecting a thing. That's kind of the whole point. Roughly speaking, a microdose lands somewhere between a tenth and a twentieth of a recreational dose. For the most common substances people use, that works out to: Finding your dose is genuinely a trial-and-error process. People who are sensitive to serotonergic compounds can feel noticeable effects at amounts that another person wouldn't register at all. The rule of thumb most experienced microdosers follow: if you can feel it, you took too much. A proper microdose should slide under your perception, not announce itself. The protocol most people reference comes from researcher James Fadiman, who suggested dosing once every three to four days for around ten weeks, then taking a break. The logic is partly about tolerance — psychedelics build it fast — and partly about not letting the practice become invisible background noise. Others run shorter cycles, or use a two-days-on, one-day-off rhythm. There's no single right answer, and frankly, anyone who tells you there is hasn't been paying attention. The reasons cluster into two broad camps. The first is mental health — people dealing with depression, anxiety, PTSD, ADHD, or OCD who either haven't responded well to conventional medication or don't love the side effects that come with it. The second is what you might call optimization — focus, creativity, energy, mood, the feeling of being a little more present and a little less stuck in your own head. The mental health angle is where things get interesting, and where I see the most readers genuinely curious. If you've been on SSRIs for a decade and you're tired of feeling emotionally flattened, the idea of a sub-perceptual dose of psilocybin twice a week sounds appealing. Journalist Erica Avery wrote publicly about microdosing LSD lifting her out of a depressive episode, and writer Ayelet Waldman built a whole book around her experience doing the same. Waldman's depression stayed gone after she stopped. Avery's came back — and she eventually concluded that occasional larger doses worked better for her than ongoing small ones. Which is the most honest thing anyone can say about this practice: your mileage will vary. Dramatically. Here's where I have to put on my skeptic hat, because the gap between what people report anecdotally and what controlled studies have found is bigger than the microdosing community generally admits. The obvious worry with any sub-perceptual practice is that the effects are mostly placebo. You believe the tiny dose will help, so it does. That's not nothing — placebo effects are real and clinically significant — but it matters for the question of whether the molecule itself is doing anything. A double-blind, placebo-controlled trial published in Biological Psychiatry in 2019 tried to answer this. Researchers gave healthy volunteers LSD at 6.5, 13, and 26 micrograms versus a placebo. They found dose-related effects on subjective experience — feelings of vigor went up, but so did anxiety. Creativity scores actually got worse on LSD. Cognitive performance didn't improve. None of which lines up neatly with the rosy reports you read online. One of the researchers noted that benefits might only show up after repeated dosing over time, which the study didn't measure. And the 26-microgram dose is arguably no longer a microdose at all — most harm-reduction guides classify it as a low recreational dose. So the picture is muddier than either side of the debate likes to admit. Fadiman ran a much larger observational study with over a thousand participants across 59 countries. People microdosing LSD or psilocybin roughly every three days reported improvements in mood, productivity, focus, energy, relationships, and health habits. Some had even tapered off antidepressants in favor of microdosing. Encouraging — but it's a self-report study with no control group. Fadiman himself was careful to note that people whose primary issue is anxiety probably shouldn't microdose, because some users find it amps anxiety up rather than down. That tracks with the controlled trial. A 2019 rodent study found that microdoses of DMT given over seven weeks improved measures of depression and anxiety without messing with cognition. Promising, but it's rats, not people, and the leap from rodent brain to human depression is famously treacherous. We don't have meaningful human data on microdosing DMT for mental health yet. A few things I think are worth saying plainly: This is probably the question that matters most for readers weighing a retreat. Microdosing and ceremonial plant medicine are different tools doing different jobs. A microdose is a quiet nudge to your nervous system, maybe useful for taking the edge off a difficult month or unsticking a creative block. A full ayahuasca ceremony, or a psilocybin retreat with experienced facilitators, is something else entirely — a full confrontation with whatever you've been carrying. People recovering from addiction, in particular, tend to find that microdosing alone doesn't get them where they need to go. The research on psychedelics and addiction recovery — the work on ibogaine for opioid dependence, psilocybin for alcohol use disorder, ayahuasca for trauma underlying substance use — involves full doses in carefully held settings, not sub-perceptual experiments at the kitchen table. That said, some people use microdosing as a gentle on-ramp. A way to develop a relationship with these compounds and notice how their own system responds before committing to a multi-day retreat. There's logic to that, as long as you're honest about what microdosing can and can't do. If you're chronically anxious, on psychiatric medication, or already suspect you're someone who reacts strongly to substances, the honest answer is probably no — or at least not without serious thought and ideally a clinician who knows what you're up to. If you're a generally stable person curious about what a slightly quieter mind might feel like, and you have access to reliable material, it might be worth a careful experiment. Start lower than the standard protocol. Keep a journal. Take real breaks. Pay attention to what changes and what doesn't. And if what you're really looking for is the deeper work — the kind that addresses trauma, addiction, or the persistent sense that something in your life is stuck — microdosing is unlikely to be the whole answer. For readers who want to explore the fuller path, a curated range of psychedelic and plant-medicine retreats can be browsed on our marketplace here. Whatever direction you go, go slowly. These compounds reward patience and humble the people who don't bring it.
Cacao Ceremony: What It Really Is, How It Feels, and Why It Matters
The first time I drank ceremonial cacao, I was sitting on a damp log in a pine forest in Maine, full moon overhead, expecting something resembling hot chocolate. What landed in my wooden cup was darker, grittier, and considerably more bitter than anything I'd associated with the word “chocolate.” I sipped it anyway. An hour later, I understood I'd been drinking the wrong cacao my entire life. This isn't a story about a psychedelic blowout. Cacao isn't ayahuasca. It won't dissolve your ego or send you spiraling through fractal jungles. But for a lot of people moving through the broader world of plant medicine and psychedelic healing, cacao has become a kind of gentle on-ramp — a way to learn what it feels like to sit in ceremony, drop into the body, and meet a plant with respect before encountering something stronger. If you're researching retreats and you keep seeing cacao mentioned alongside ayahuasca, San Pedro, and psilocybin, here's what's actually going on. A cacao ceremony is a ritual gathering — usually in a circle, often around a fire or altar — where participants drink a strong dose of ceremonial-grade cacao prepared with intention. There's typically a facilitator or shaman holding the space. There may be songs, prayers, silence, breathwork, journaling, or movement. The specifics vary wildly depending on the lineage and the facilitator's training. The cacao itself is the centerpiece, and this is where most newcomers get tripped up. Ceremonial cacao is not the cocoa powder in your pantry. The cacao fruit is harvested in Central or South America, fermented to strip away the pulp, and the beans are ground whole into a thick paste. Nothing is removed. No fats stripped out, no alkaloids isolated, no sugar dumped in. It's the full, unaltered plant. The comparison I keep coming back to: store-bought cocoa is to ceremonial cacao what a fast-food orange juice pouch is to a freshly squeezed orange. Same family. Different universe. Cacao has been used ceremonially for thousands of years across what we now call Mexico, Guatemala, Belize, and Honduras. The Maya and Aztec civilizations treated it as sacred — a food for royalty and a medicine for ritual. It appeared in marriage ceremonies, in offerings to deities, in funerary rites. The word "cacao" itself traces back to Mesoamerican languages, and archaeological residue testing has found cacao traces in ceremonial vessels dating back over three millennia. The modern revival, mostly Western-led and concentrated around facilitators in Guatemala, Bali, Costa Rica, and the U.S. wellness scene, is a more recent phenomenon. Some of it honors the original traditions carefully. Some of it doesn't. As with any plant medicine making the leap from indigenous context to global retreat circuit, there's a wide spectrum of integrity out there. Worth knowing before you book. No. Not in the way ayahuasca, psilocybin, or ibogaine are psychedelic. You won't hallucinate. You won't lose your sense of self. You won't see geometric patterns or commune with entities from other dimensions. If that's what you're after, cacao isn't your medicine. What cacao does is more subtle, and that subtlety is exactly why some people dismiss it and others swear by it. The active compounds — theobromine, anandamide, phenylethylamine, magnesium, a small amount of caffeine — work together to gently elevate mood, increase blood flow, soften the nervous system, and open up emotional access. Theobromine is a vasodilator; you'll often feel warmth spreading through your chest within twenty or thirty minutes. Anandamide is sometimes called the “bliss molecule.” Phenylethylamine is associated with feelings of attraction and connection. Put that together in a ceremonial dose (usually 30 to 45 grams of pure cacao paste, far more than a chocolate bar) and you get a state that's hard to describe but easy to recognize once you've felt it: alert but not wired, soft but not sleepy, emotionally accessible without being overwhelmed. People cry. People laugh. People sit silently for two hours and report feeling fundamentally rearranged afterward. A lot of facilitators in the broader plant medicine world use cacao as a complementary practice. There are practical reasons for this: This is part of why cacao retreats and cacao ceremonies are increasingly stitched into broader plant medicine programming, especially in places like Guatemala's Lake Atitlán region, Costa Rica's Nicoya Peninsula, and parts of Bali. Every facilitator does this differently, but the rough arc tends to look something like this. You arrive, leave your shoes at the door, and find a cushion in the circle. There's usually an altar in the center — flowers, candles, sometimes crystals or feathers, sometimes nothing more than a single carved wooden bowl. The facilitator opens the space, sets intentions, may invoke directions or sing an opening song. Then the cacao is served, cup by cup, often with eye contact and a quiet exchange. You sit with your cup. You set your own intention — what you're sitting with, what you're asking for, what you want to release. You drink. The next two to four hours are loosely held. There might be guided meditation, ecstatic dance, sharing circles, breathwork, or extended silence. The facilitator's job is to hold the container, not to direct your experience. You go where the medicine takes you, which for cacao usually means somewhere quieter and more emotionally honest than your day-to-day mind. Cacao is broadly safe, but it isn't for everyone. A few honest caveats: The cacao world ranges from deeply traditional Maya-rooted ceremonies led by indigenous abuelas in Guatemala to weekend wellness pop-ups in converted yoga studios run by someone who took a five-day training. Both can be meaningful. Neither is automatically legitimate just because it's labeled “ceremony.” A few things to look for: For readers who want to take this further, a range of curated cacao and plant medicine retreats can be browsed on our marketplace here. Whether cacao becomes a standalone practice or a doorway into deeper psychedelic and plant medicine work, the value is the same: you learn what it feels like to actually sit with a plant, ask it something, and listen to what comes back.
Inside the Psilocybin Microdosing Boom: What Founders, Doctors, and Researchers Actually Say
Somewhere between the third espresso and the fourth Slack message, a quiet experiment is unfolding in the tech world. Founders, VCs, and operators — people who would happily debate Series A term sheets at midnight — are dropping crumb-sized amounts of psilocybin into their morning routine and reporting back like amateur neuroscientists. Welcome to the so-called shroom boom, where ayahuasca, psychedelics, addiction recovery conversations, and the older idea of master plants are colliding with the productivity industrial complex. It’s a strange moment. Magic mushrooms — the same fungi that defined a generation of 1960s counterculture — are now being microdosed before pitch meetings. Whether that’s a genuine evolution in human wellness or a tech-bro repackaging of an ancient sacrament depends on who you ask. So let’s actually ask. A microdose is small. Really small. Researchers like Dr. James Fadiman, who has spent decades documenting the practice, define it as roughly one-twentieth to one-tenth of a recreational dose — enough to nudge the nervous system, not enough to send you into the cosmos. You don’t hallucinate. You don’t see the walls breathe. Ideally, you barely notice anything other than feeling a touch more present. People microdose all sorts of substances: psilocybin mushrooms, LSD, occasionally cannabis, and in rarer cases sub-perceptual amounts of DMT or even ayahuasca tinctures. Psilocybin is by far the most popular because it’s organic, relatively forgiving, and — at the moment — culturally fashionable. Protocols vary. Some follow Fadiman’s one-day-on, two-days-off cycle. Others do two days on, five off. A few people just take it when they feel like it, which researchers tend to politely call “not a protocol.” And no, it’s not the same as sitting in a ceremony with a curandero and drinking a cup of brewed master plants for eight hours. A microdose is the opposite experience — quiet, undramatic, almost boring. That’s the point. The anecdotal case is consistent enough to be interesting. Founders describe sharper focus, less anxious chatter, a sense of being able to listen properly in conversations. One beverage entrepreneur in Florida told reporters that after he started microdosing, he found himself less reactive and more open — fewer doses of caffeine, fewer panicked spirals between meetings. A Los Angeles wellness founder calls her routine a “nano-dose,” about an eighth of a full dose, taken a few mornings a week. She says it dissolves anxiety the way a hot bath dissolves muscle tension. A former Canadian finance consultant turned psychedelic educator put it most bluntly: microdosing, she says, let her get three days of work done in one. She’s now built a small business around teaching others to do the same. You hear a few themes again and again from people who microdose seriously: That last one is interesting. Microdosers often say the effect compounds across the week, rather than living and dying inside the dose itself. Whether that’s real or a story they’re telling themselves is exactly where the science gets wobbly. Here’s the honest version. Macro-dose psilocybin research — full ceremonial doses given in clinical settings — is genuinely promising. There are well-designed trials showing meaningful effects on treatment-resistant depression, end-of-life anxiety, and addiction recovery, particularly for alcohol and nicotine dependence. That body of work is one of the reasons psychedelics, addiction, and mental-health treatment now share so much real estate in medical journals. Microdosing is a different story. The randomized, double-blind studies that do exist tend to show modest effects, much of which can be explained by expectation. As one Harvard-affiliated physician researcher has pointed out, almost everyone who microdoses believes it helps them, but the trials don’t cleanly confirm it. Creativity, focus, presence — these aren’t cholesterol levels. They’re slippery to measure. The gold-standard trial design doesn’t translate well to subjective wellness gains. That doesn’t mean microdosing is fake. It means we’re early. The psychedelic research renaissance has had perhaps two decades of serious momentum, and most of that funding has gone toward the more dramatic, easier-to-measure clinical applications. Microdosing science is still catching up. Under United States federal law, psilocybin is a Schedule I controlled substance. Possession is illegal. That’s the headline. The fine print is more interesting: Oregon allows supervised adult use through licensed service centers, Colorado has moved in a similar direction, and cities including Denver, San Francisco, Oakland, Seattle, and Minneapolis have decriminalized personal possession to varying degrees. Several state-level legalization efforts have stalled. Canada, meanwhile, is racing ahead with a patchwork of clinics, retreats, and brick-and-mortar mushroom shops operating in legal grey zones. So legality depends entirely on where you’re standing when you swallow the capsule. None of this is legal advice — please do your own homework based on your jurisdiction. As for safety, microdosing is generally considered lower-risk than full-dose use, but “lower risk” doesn’t mean “no risk.” A few honest caveats worth knowing: For a lot of people, microdosing isn’t the destination — it’s the doorway. Curious about psilocybin in small amounts, they eventually start reading about full-dose experiences, about ayahuasca, about the long-standing traditions of plant medicine and master plants in the Amazon and the Andes. That’s a meaningful step up in intensity, and it deserves a different kind of preparation. If you’re weighing a retreat — psilocybin, ayahuasca, San Pedro, or something else in the plant-medicine family — a few things are worth thinking about before the credit card comes out. Who runs the retreat? What lineage or training do the facilitators come from? What’s the medical screening process? What does integration support look like in the weeks after you fly home? Is there a real container around the experience, or is it essentially a vacation with a substance attached? The good retreats tend to ask you as many questions as you ask them. The questionable ones take your deposit before they’ve learned your last name. A retreat is not a productivity hack. It’s an experience that can reshape how you see your life, and the people guiding it matter enormously. There’s a strange double life happening in tech right now. Some founders talk openly about their psilocybin practice on podcasts. Others won’t mention it out loud, even with VCs they suspect are doing the same thing. The 2021 firing of an Iterable CEO who admitted to dosing LSD before a meeting still hangs in the air as a cautionary tale. That stigma is shifting, slowly. Investors are pouring money into psychedelic biotech. Cities and states are loosening laws. The conversation around psychedelics, addiction recovery, and mental health is moving from fringe to mainstream faster than almost anyone predicted ten years ago. Still, the most thoughtful people in this world tend to caution against treating mushrooms as a life hack. The traditions that have used these plants for centuries don’t talk about productivity. They talk about humility, listening, and being changed by something larger than yourself. Worth holding both ideas at once. If you’ve read this far, you’re probably not looking for a hot take. You’re trying to figure out whether any of this is for you. A few honest suggestions: For readers who want to take this further, a range of curated psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. These are old medicines moving through a very new world, and the people who get the most out of them tend to be the ones who took their time getting in.
Oregon's Psilocybin Law: What Legal Magic Mushrooms Actually Mean for You
When Oregon voters passed Measure 109, something shifted in the American psychedelic landscape that we're still living with the consequences of. Psilocybin — the active compound in so-called magic mushrooms — became legal for therapeutic use, with the state itself overseeing how it would be grown, distributed, and administered. No doctor's note required. No prescription pad. Just a framework, slowly being built, for adults to access psilocybin in a supervised setting. That was years ago now, and the rollout has been messier and more interesting than anyone predicted. If you're sitting in 2026 wondering whether Oregon's program is actually a path you can walk, or whether it's relevant to your own thinking about a psilocybin retreat, this is the honest version of where things stand and what it means. Let's get the basics out of the way. Measure 109 created a state-licensed program for the supervised use of psilocybin by adults. It did not make mushrooms legal to grow in your backyard, sell to your neighbor, or take recreationally. Possession outside the licensed framework is still illegal under Oregon law, though a separate ballot measure decriminalized small personal amounts to the lowest law-enforcement priority. The companion piece — the one most people miss — is that none of this changes federal law. Psilocybin remains a Schedule I substance at the federal level, which means the DEA still classifies it as having no accepted medical use. The state and the feds are essentially looking past each other on this, which is the same uneasy arrangement that's been propping up state cannabis programs for years. What you get inside Oregon is a service model. You show up at a licensed service center, you go through a preparation session with a licensed facilitator, you take a measured dose of psilocybin produced by a licensed manufacturer, and you stay there — often for six to eight hours — while a facilitator sits with you. Then there's an integration conversation afterward. It's not therapy in the clinical sense (facilitators aren't required to be therapists), and it's not a free-for-all either. The research story is what makes all of this more than a policy curiosity. Over the past decade, work out of Johns Hopkins, NYU, and a handful of other institutions has produced some of the most striking mental-health results in modern psychiatry — particularly for people who haven't responded to conventional antidepressants. Studies on treatment-resistant depression, end-of-life anxiety in cancer patients, and tobacco and alcohol addiction have all shown effects that, frankly, would be considered remarkable if they came from a pharmaceutical pill. A few things stand out in that literature. The effects tend to come from a small number of doses — sometimes just one or two — rather than daily medication. They seem to persist for months. And they appear to work through something psychologically meaningful, not just a chemical lever. People describe sessions that reframe how they relate to grief, fear, or the patterns they've been stuck in for years. None of this is a guarantee that a psilocybin session will fix what's wrong, and serious researchers are careful to say so. The data is promising; it isn't a finished story. But it's strong enough that ignoring psilocybin's potential, as a category of medicine, has gotten harder to defend. This is where people get confused, and it matters if you're trying to make a real decision. Oregon's service-center model is not a multi-day retreat in the traditional sense. You don't typically stay overnight. You don't typically join a group ceremony with songs and ritual. It's closer to an outpatient session — show up, sit with a facilitator, have your experience, go home (or to a hotel) once you're cleared to leave. Retreats, by contrast, usually involve several days of preparation, multiple ceremonies, group meals, and structured integration time. They draw on lineages — Mazatec, Amazonian, contemporary therapeutic — that shape how the medicine is offered. Some are run in jurisdictions where psilocybin is legal or unregulated (the Netherlands has long had a workaround using psilocybin truffles; Jamaica has hosted retreats for years). Others operate in the gray zones of various countries. Each model has trade-offs: Which one fits depends on what you're after. Someone working with end-of-life anxiety might want the medicalized, closer-to-home option. Someone exploring chronic depression or a long-standing stuck pattern might want the deeper container of a retreat. Neither is automatically better. Here's the part that surprises people. A single supervised psilocybin session in Oregon often runs anywhere from $1,500 to $3,500 once you factor in the preparation meeting, the dosing session, the facilitator's time, the product itself, and integration. Insurance doesn't cover it. That's not the program's fault — building this kind of infrastructure from scratch is expensive — but it has meant that the people who can access psilocybin legally in the U.S. tend to be the people who could already afford a flight to a retreat somewhere else. Retreats abroad range widely too. A short psilocybin retreat in the Netherlands can run $2,000 to $4,000 including lodging and meals. Longer programs with more ceremonies push higher. The famous Jamaica retreats have charged in the five-figure range for premium experiences. The point is, no path here is cheap, and the legal options haven't yet delivered the affordability that early advocates hoped for. If you're reading this because you're considering psilocybin for depression, anxiety, addiction, grief, or just a long stuck feeling that won't shift, a few questions are worth sitting with before you book anything. One thing I'd push back on, gently: the framing that psilocybin is a cure. The research is genuinely exciting, and people do have experiences that change their lives. But the substance is a doorway, not a destination. What you do in the weeks and months after — therapy, lifestyle change, the slow work of putting insights into practice — is where the real shift happens or doesn't. Colorado has since passed its own program with a somewhat different design. Other states have introduced bills, working groups, and pilot programs at various stages. The FDA has continued to grant Breakthrough Therapy designation to psilocybin-assisted treatment for major depression, which signals that the federal landscape is at least slowly moving. Clinical trials have multiplied. Insurance reimbursement is still mostly a fantasy, but there's chatter about pilot programs. The retreat world has also matured. There are more facilitators with serious training, more lineages openly teaching, more honest conversation about what can go wrong, and — importantly — more public reckoning with bad actors. The early years of this resurgence had a tendency to treat every charismatic guide as enlightened. That's softened into something more discerning, which is good for everyone. For readers ready to look at specific options, a curated selection of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whether you end up in Oregon, abroad, or simply continue researching for another year, the most important step is the one most people skip: getting clear, before you book anything, on what you're actually hoping the medicine will help you with.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
Oregon Psilocybin Law: What's Legal, What Isn't, and Why It Matters for Retreat-Seekers
A few years back, a small herbal shop in Portland made the kind of headlines that confuse the hell out of anyone trying to understand where psychedelics actually stand in the United States. People lined up around the block. They filled out questionnaires. They walked out with bags of psilocybin mushrooms — varieties with names like Penis Envy and Albino Golden Teacher — paying somewhere around $85 to $95 for seven grams. The shop framed itself as Oregon's first licensed psychedelic dispensary. It wasn't. Not even close. And the gap between what was happening on that sidewalk and what Oregon's psilocybin law actually permits is exactly the kind of confusion that trips up people researching plant medicine, master plants, and psychedelic retreats. If you're weighing whether to spend real money on a retreat, you need to understand this landscape clearly — because the difference between a legal therapeutic container and an unregulated transaction has real consequences for your safety, your wallet, and your healing. Oregon passed Measure 109 — the Oregon Psilocybin Services Act — back in November 2020. It was the first state-level psilocybin law of its kind in the country, and it was a genuine milestone for psychedelic-assisted recovery. But the measure didn't do what a lot of casual readers assume it did. It did not decriminalize mushrooms. It did not legalize recreational sale. It did not turn psilocybin into something you can pick up alongside your kombucha. What it created was a tightly regulated framework for supervised therapeutic use. Under Measure 109, psilocybin can only be consumed at a licensed service center, in the presence of a licensed facilitator, by someone who has gone through a preparation session. There is no take-home model. There is no retail counter. There is no path — present or planned — for buying mushrooms over the counter and walking out with them. Sam Chapman, who runs the Healing Advocacy Fund, put it about as plainly as anyone can: nothing in Measure 109, and nothing in any other Oregon law, permits the retail sale of psilocybin mushrooms. Not today, not in the future as the law is currently written. The state's licensed services exist because Oregonians dealing with depression, anxiety, and addiction stand to benefit from psilocybin — but only when the therapy is delivered safely, with screening, integration, and a trained guide. The Shroom House situation is a useful case study in what happens when commercial momentum runs ahead of regulation. Customers were asked to join a so-called "Shroom House Society," show two forms of ID, prove they were over 21, and fill out a questionnaire that asked about mental health history. From a distance, that paperwork looks vaguely clinical. Up close, it's a loyalty card with extra steps. A reporter who walked in was apparently buying within five minutes of finishing the form. A former employee eventually went to local news and said management had told staff the shop was the first medically sanctioned psychedelic retailer in the state. It wasn't. The Oregon Health Authority hadn't even started issuing facilitator and service-center licenses yet. The shop was operating in a legal vacuum that didn't actually exist — psilocybin is still a Schedule I substance under federal law, and at the time, no Oregon entity had authority to sell it commercially under state law either. The honest takeaway here isn't outrage. It's the recognition that wherever there's genuine therapeutic demand and unclear regulation, opportunists will find the seam. For anyone researching psychedelics seriously — especially anyone hoping to use them for addiction or depression — knowing the difference between an above-board therapeutic container and a guy with a storefront is essential. Compare the Portland storefront with what an actual psychedelic retreat involves and the contrast becomes obvious. Whether we're talking about psilocybin services in Oregon, ayahuasca ceremonies in the Peruvian Amazon, ibogaine in Mexico, or San Pedro in the Andes, the legitimate end of this world shares a common shape: None of that is what happens when you buy mushrooms over a counter and take them home. That's not a retreat. That's not therapy. That's a transaction, and any framing that suggests otherwise is doing the medicine — and the people it might help — a disservice. The honest answer is: increasingly, the evidence says yes — but the conditions matter enormously. Clinical research on psilocybin for alcohol use disorder, ibogaine for opioid dependence, and ayahuasca for various substance and behavioral addictions has been quietly accumulating for two decades now. The trial results aren't fringe anymore. Johns Hopkins, NYU, Imperial College London — serious institutions are publishing serious data on psychedelic-assisted recovery, and the early signal is that these compounds can interrupt patterns that years of conventional treatment couldn't budge. That said, master plants and synthetic psychedelics aren't magic. They're powerful tools that work best when held inside a real therapeutic process. Someone in active addiction who buys mushrooms at a storefront and dips in alone is not running the same intervention as someone going through a screened, prepared, facilitated session. The substance might be identical. The outcome rarely is. Set and setting — that old Leary phrase — turns out to be more than a slogan. It's most of the medicine. This is why the legal framework Oregon is building, slow and frustrating as it can feel, actually matters. A regulated facilitator model creates the conditions under which psilocybin's therapeutic potential can show up reliably. A storefront free-for-all creates the conditions under which people get hurt and the whole movement gets a black eye. Here's the practical takeaway. If you're someone quietly considering plant medicine — for a stuck depression, a trauma you can't seem to metabolize, an addiction that has outlasted every other intervention — the Portland story is a useful warning. The space is filling up with operators whose understanding of safety ranges from excellent to nonexistent. Marketing language and clinical legitimacy are not the same thing. A few things worth checking before you commit money or travel: The psychedelic-assisted recovery field is in a strange adolescent phase right now. The laws are catching up unevenly. The science is racing ahead. And in the gap between the two, both genuine healing centers and outright opportunists are setting up shop. Your job as a researcher — and a potential participant — is to tell them apart. If you've read this far and want to keep exploring legitimate options, a range of vetted psilocybin and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and the right container is worth waiting for.
Vancouver's Magic Mushroom Dispensaries: Civil Disobedience or Legalization Strategy?
Walk down certain blocks of East Vancouver and you'll spot something that probably shouldn't exist under federal law: storefronts openly selling psilocybin. Chocolates, capsules, dried caps in glass jars. No back rooms, no whispered passwords. Just a counter, a price list, and a clerk who'll happily explain the difference between a microdose and what they call a “heroic” one. It's strange. It's a little brazen. And if you've been following the slow, uneven march of psychedelics from underground curiosity to clinical research darling, it's also very, very familiar. Because this exact playbook — open a shop, dare the authorities to shut you down, force the conversation — is how Canada ended up legalizing cannabis. Now a handful of activists are running the same experiment with magic mushrooms, and the rest of us get to watch in real time. Psilocybin is a controlled substance under Canadian federal law. Selling it is illegal. And yet, in Vancouver, a small but growing cluster of dispensaries does exactly that — out in the open, with signage, social media accounts, and customer reviews. The most visible operator is Dana Larsen, a longtime drug-policy activist who runs the Medicinal Mushroom Dispensary out of the same space as his Coca Leaf Café. He started selling psilocybin chocolates and capsules to walk-in customers a few years back, and he's been pretty transparent about his strategy: keep selling, get noticed, force the government to either crack down hard or move toward regulation. So far the government has done neither, which is its own kind of answer. Other shops have followed. Some opened during the pandemic to make up for lost revenue from cannabis or other businesses. A few are run by people who genuinely believe psilocybin should be available for therapeutic use and are tired of waiting for Ottawa to catch up. The Vancouver Police have said mushroom prosecutions aren't a top priority. City Hall has sent some sternly worded letters. The shops are still open. Here's the thing about Vancouver: this city has been a testing ground for drug-policy civil disobedience for decades. Illegal cannabis dispensaries operated openly there from at least 2015, with the city eventually creating a municipal licensing system — even though selling weed was still federally illegal at the time. Three years later, Canada legalized recreational cannabis nationwide. Was that legalization the direct result of grey-market shops? Probably not entirely. But the shops normalized the conversation. They made it impossible for politicians to pretend the demand wasn't there. They gave the public a chance to see, for years, that the sky didn't fall. By the time Parliament got around to writing legislation, the cultural battle was largely over. The mushroom dispensary owners are betting the same dynamic will play out again. The bet isn't crazy. Psilocybin research is moving fast — clinical trials at major universities, Health Canada granting individual exemptions for people with terminal illness or treatment-resistant depression, and a steady drip of mainstream media coverage that treats the molecule as medicine rather than menace. The legal frame is wobbling. Someone was always going to push. Let's pause on the medical claim, because it matters. There's now a real body of clinical evidence suggesting that psilocybin — typically administered in larger, supervised doses alongside psychotherapy — can produce meaningful and sometimes lasting reductions in depression and anxiety, including for people who haven't responded to standard treatments. It's also being studied for addiction, end-of-life distress, and a handful of other conditions where the conventional pharmaceutical toolkit has been underwhelming. This isn't fringe stuff anymore. It's published in peer-reviewed journals. It's drawing real money into psychedelic biotech. A psychedelic-focused exchange-traded fund launched on a Canadian exchange a few years ago, which is roughly the most boring possible signal that a thing has gone mainstream. Microdosing — taking sub-perceptual amounts on a regular schedule — is a different story. The popular case for it has run well ahead of the data. Some researchers find modest mood and creativity effects; others find that most of what people report is placebo. If you're considering microdosing for a specific mental health issue, the honest answer is: the jury's still out, and a properly supervised larger-dose session may have far stronger evidence behind it. Even with the shops operating openly, psilocybin remains illegal to sell or possess in Canada outside narrow exemptions. Health Canada does grant individual access through its Special Access Program, and there's a Section 56 exemption pathway, but both processes are slow, paperwork-heavy, and require specific medical circumstances. A not-for-profit called TheraPsil has spent years helping patients — especially those facing terminal diagnoses — navigate the bureaucracy. Many people give up and turn to grey-market shops or underground guides instead. In the United States, the picture is more fragmented. Federally, psilocybin is Schedule I. But Oregon has rolled out a regulated psilocybin services program, Colorado has decriminalized personal possession and is building out its own framework, and a growing list of cities — Denver, Oakland, Seattle, Detroit, several others — have effectively deprioritized enforcement. None of this makes it legal to buy mushrooms at a shop the way Vancouverites can. But the legal terrain is shifting fast enough that anything written about it has a short shelf life. If you've read this far, there's a decent chance you're not just curious about Canadian drug policy. You're weighing whether a psychedelic experience — mushrooms, ayahuasca, something else — might actually help with something specific. Depression that won't budge. A drinking problem. Grief. A sense that you've been on autopilot for years and can't find the off switch. A few honest things to consider before you walk into any dispensary or book any retreat: Vancouver's mushroom shops won't be the last act in this story. Whether they get raided, regulated, or quietly absorbed into a future legal framework, they've already done some of the work activists wanted them to do — they've made psilocybin visible, debatable, and increasingly unavoidable as a policy question. Other cities will follow. Some governments will move quickly; others will dig in. For individuals trying to figure out whether plant medicine has a real role in their own life, the better path is usually slower than walking into a shop. It involves reading widely, talking to people who've done the work, screening yourself for real medical risks, and choosing a setting with trained facilitators and a clear integration plan. Retreats — especially ones in jurisdictions where the practice is legal or traditionally protected — remain the most evidence-supported way most people access these experiences. If you're starting that research, a range of curated psilocybin and plant-medicine retreats can be explored on our marketplace here. The Vancouver dispensaries are an interesting symptom of where the culture is going. They're probably not where your own story should start.
Can Psychedelics Help Fighters Heal Brain Trauma? Inside the UFC's New Research Push
A retired fighter forgets his own children's names. He gets dizzy walking across the kitchen. Last week, he says, is a blur. This isn't a scene from a documentary about boxing in the 1970s — it's the reality being described, right now, by men who fought professionally less than a decade ago. And it's the reality that has pushed one of the biggest combat-sports organizations in the world to start asking a question that would have been unthinkable a few years back: could psychedelics actually help? The UFC has quietly opened the door to exploring psychedelic-assisted therapy as part of its broader brain-trauma research, and the implications stretch far beyond the octagon. If plant medicine can offer something for fighters carrying years of accumulated damage, what does that say about the wider potential of substances most of the world still classifies as illegal? It's a strange moment in the story of psychedelics — one where the conversation has moved from underground ceremonies to press conferences with cage fighters. The shift didn't happen in a vacuum. For years, former fighters have spoken in hushed tones about cognitive decline, mood collapse, suicidal ideation, and the personality changes that often arrive in their forties. The condition has a name — chronic traumatic encephalopathy, or CTE — and it's a problem the sport has been slow to address publicly. When a recent feature documented one former UFC competitor's diagnosis of permanent disability, with memory loss severe enough that he sometimes forgets which child he's speaking to, the conversation got harder to dodge. UFC president Dana White acknowledged the obvious in a follow-up interview: this isn't one fighter's misfortune. It's structural. Anyone who has done this long enough is dealing with something. He called it part of the gig — which is honest, even if it's bleak. What's new is that the organization has signaled it wants to do more than nod sympathetically. A multi-year extension of its partnership with the Cleveland Clinic, plus a substantial donation to the Lou Ruvo Center for Brain Health in Las Vegas, set the stage. Then White name-dropped the psychedelic researchers at Johns Hopkins, and suddenly the story changed shape. The trigger appears to have been a televised feature on retired professional athletes — football players, mostly — who turned to psilocybin and ayahuasca after their careers ended. They described relief from depression, from rage, from the suffocating fog that follows years of head trauma. Their stories aren't peer-reviewed, but they're not nothing either. They're the kind of testimony that makes institutions pick up the phone. The Center for Psychedelic and Consciousness Research at Johns Hopkins has spent the last decade and a half building a serious body of work on substances like psilocybin and LSD. They've published dozens of peer-reviewed papers covering addiction (nicotine, alcohol, and other dependencies), end-of-life anxiety in cancer patients, and treatment-resistant depression. The results have been striking enough that the FDA has granted breakthrough-therapy status to psilocybin for depression, which is not the kind of designation a regulator hands out casually. What we don't yet have — and this is important — is a robust body of evidence specifically on psychedelics for traumatic brain injury. The mechanisms researchers are excited about are suggestive rather than proven. Psilocybin appears to promote neuroplasticity, meaning the brain's capacity to form new connections. Some animal studies have shown growth in dendritic spines after a single dose. For a brain that's been concussed dozens or hundreds of times, the idea of a compound that might literally help neurons reorganize is, understandably, electrifying. But excitement isn't proof. The leap from "helps depressed patients" to "repairs cumulative head trauma" is enormous, and any honest researcher will tell you we're nowhere near making it confidently. What's happening now is the early-stage work of asking whether the question is even worth pursuing. The fact that a major sports body is funding part of that question is itself remarkable. Step back from the UFC story for a moment, because something larger is going on. Across North America, attitudes toward psychedelics have shifted with surprising speed. Oregon legalized supervised psilocybin use. Several cities have decriminalized natural psychedelics. Veterans' groups have become unlikely advocates for ibogaine and ayahuasca, citing dramatic relief from PTSD that conventional medication never delivered. The conversation that lived in Amazonian ceremony huts and underground therapy circles is now happening in legislatures, hospitals, and yes, mixed-martial-arts boardrooms. The plants and compounds at the center of this shift are sometimes called master plants by the traditions that have used them for centuries — ayahuasca, peyote, San Pedro, iboga, certain mushrooms. The term carries a specific meaning: these aren't recreational substances in the cultures that birthed their use. They're considered teachers, agents that show a person something about themselves they couldn't otherwise see. Whether you take that framing literally or metaphorically, it points at something the clinical research keeps confirming — these compounds tend to produce experiences that feel meaningful, and that meaning seems to be part of why they work. For someone recovering from addiction, the experience often involves seeing one's relationship to the substance with terrible clarity. For someone in depression, it can briefly dissolve the walls that the depressed mind builds around itself. For someone carrying trauma — including, perhaps, the kind of trauma a fighter accumulates — it may offer access to material the conscious mind has buried. None of this guarantees healing. But it changes what's possible. If you're reading this because you've been quietly researching plant medicine for your own reasons — not because you fight professionally, but because something in your life has gotten stuck — the UFC story matters in an indirect way. Institutional interest tends to drag taboos into daylight. When a sports organization openly explores psychedelic therapy, it gives cover to the doctor who's been quietly curious, the therapist who has clients asking about it, the family member who didn't know how to bring it up. The conditions where psychedelics have shown the most consistent results in trials so far include: The picture that emerges from these studies isn't of a miracle drug. It's of a tool that, used in the right context with the right preparation and integration, can produce shifts that years of conventional treatment couldn't. The right context matters enormously. A psychedelic dose taken in a clinical or ceremonial setting, with trained support before and after, is a completely different experience from the same dose taken alone at a music festival. The compound is the same. The outcome rarely is. People reading articles like this one often have a quieter question underneath: should I actually do this? It's worth being honest about what a retreat involves, because the romanticized version doesn't survive contact with the reality. A real ayahuasca or psilocybin retreat is physically demanding, emotionally raw, and occasionally terrifying. Participants vomit. They cry. They confront memories they've spent decades avoiding. The cliché of "sitting with your stuff" is accurate, and the stuff is rarely pleasant company. What separates a well-run retreat from a risky one isn't the location or the marketing — it's the people running it and the support structure around the medicine. A few things worth checking before you commit: The cost varies wildly — anywhere from a thousand dollars for a short domestic retreat in places where local laws allow, to ten thousand or more for longer stays in Peru, Costa Rica, or Mexico with extensive medical support. Expensive isn't automatically better. Cheap isn't automatically suspect. What matters is the fit between what's offered and what you actually need. It's worth pausing on how unlikely this moment is. A combat-sports organization, a major medical research center, indigenous traditions from the Amazon, neuroscientists at a top-tier university, and ordinary people quietly weighing whether to book a retreat — all of them, in different ways, are circling the same question. What if the substances we've spent fifty years criminalizing turn out to be among the most useful tools we have for the things modern medicine struggles most with? The answer won't be a clean yes. It will be messy, partial, and full of caveats. Some people will be helped enormously. Others won't be helped at all. A few will have bad experiences that take years to integrate. This is true of every powerful intervention, from surgery to antidepressants to long-term therapy. What's different about psychedelics is that the conversation around them has finally caught up with what practitioners and participants have been quietly saying for decades — they do something, and that something is worth taking seriously. For readers who feel drawn to take this further — whether that means deeper reading, a conversation with a knowledgeable guide, or actually exploring a structured experience — a range of curated ayahuasca and psychedelic retreats can be browsed on our marketplace here. Whatever you decide, decide it slowly. The medicine isn't going anywhere, and the choice deserves the same care the experience itself will demand of you.
Oregon's Psilocybin Law: What Legal Mushroom Therapy Actually Looks Like
When Oregon voters approved Measure 109, something genuinely strange happened in American drug policy. A state had, for the first time, said yes to supervised, legal use of a classic psychedelic — psilocybin, the active compound in magic mushrooms — outside any research or religious-exemption framework. Not decriminalization. Not a clinical trial. An actual licensed-services model. If you're someone weighing a psychedelic retreat for depression, addiction, trauma, or just a stuck life pattern you can't seem to shake, this matters. It changes the map. I want to walk through what Measure 109 actually does, what it doesn't do, and how it fits into the bigger conversation around psychedelics, plant medicine, and addiction recovery. Because a lot of what gets repeated online is half right at best. The short version: roughly 56% of Oregon voters approved the measure. It directed the Oregon Health Authority to build a regulated program — the Oregon Psilocybin Services Program — where licensed facilitators can administer psilocybin to adult clients inside licensed service centers. Manufacture, processing, delivery, and possession of psilocybin became legal under state law, but only inside that licensed framework. Step outside it and the old criminal penalties still apply. The measure also baked in a two-year development period before the program actually opened its doors. That wasn't bureaucratic foot-dragging. Oregon was building something nobody else had built — licensing categories, training requirements, dosing rules, packaging standards, an advisory board, a tax structure. The state essentially had to invent the rulebook from scratch. A few specifics worth knowing if you're trying to understand what's actually on offer: The timing wasn't random. For most of the last decade, research out of Johns Hopkins, NYU, and Imperial College London has been publishing results on psilocybin-assisted therapy for treatment-resistant depression, end-of-life anxiety, and substance use disorders that ranged from interesting to genuinely startling. A single high-dose session, in the right setting, with proper preparation and integration, was producing sustained improvements that conventional pharmaceuticals struggle to match. That's the research backdrop. The cultural backdrop is messier and more interesting. A generation that grew up being told mushrooms would melt their brains started reading clinical papers and noticing the science said something rather different. Veterans were talking openly about psychedelic healing. People in addiction recovery were saying ibogaine and psilocybin had done what twelve-step rooms and SSRIs couldn't. The conversation around master plants — the term Amazonian traditions use for teacher-plants like ayahuasca, San Pedro, and tobacco — was bleeding into the mainstream wellness world. Oregon's vote was, in a sense, the political system catching up with what a lot of people had already quietly concluded: that these substances, used carefully, are not the menace the 1970s told us they were. Here's where I'll be honest with you. Oregon's program is real, and it's legal, and it's a meaningful option. But it's not the same animal as a traditional plant-medicine retreat in Peru or Costa Rica, and it's not trying to be. If you've been reading about ayahuasca ceremonies in the Sacred Valley or ibogaine clinics in Mexico, the Oregon model will feel different — more clinical, less ceremonial, English-speaking, regulated. Which one is right for you depends on what you're actually after. A few honest distinctions: Whether you end up in Oregon, in the Peruvian jungle, or at a psilocybin retreat somewhere in between, the same red flags apply. The legalization wave has brought in serious practitioners and also, frankly, a fair number of opportunists. A few things to look for, and a few to run from. Good signs: a thorough medical and psychological intake before you ever pay a deposit. Clear questions about your medications (especially SSRIs, MAOIs, and lithium — these interact badly with several plant medicines). A facilitator who's been doing this for years, not months. Real integration support, not a goodbye hug and a flight home. Honest conversations about who shouldn't take part — people with personal or family histories of psychosis, certain heart conditions, or untreated bipolar disorder are usually screened out for good reason. Warning signs: vague pricing, no medical questionnaire, promises of guaranteed healing, facilitators who claim to be the reincarnation of someone, group sizes that feel more like festivals than ceremonies, no aftercare plan, no way to talk to past participants. Trust your gut on this. The people doing serious work tend to feel grounded and a little boring in their professionalism. The flashy ones are often the ones to skip. One thing I'd offer to anyone reading this because they're hurting — because the depression hasn't lifted, because the drinking is back, because something inside is asking for help — is that psychedelics are a tool, not a magic eraser. The research is real. The experiences can be genuinely transformative. People do come out of a single session with shifts that years of talk therapy didn't produce. And. The work afterward is its own thing. The session opens a door. Walking through it — changing habits, repairing relationships, building the life the medicine showed you was possible — that part still belongs to you. The best retreats know this and structure their programs around it. The worst ones sell you the door and forget the rest of the house. If you're sitting with this decision, take your time. Read the research. Talk to people who've done it. Get medical clearance if there's any question. And if something here has nudged you toward exploring further, a curated selection of psilocybin and broader plant-medicine retreats can be browsed on our marketplace here. The right retreat at the right time can be a hinge in a life — but only if you walk in with eyes open.
Psilocybin and Cancer Anxiety: What Happens Five Years After a Single Dose
One dose. That's what the cancer patients in this trial received. A single, carefully supervised session with psilocybin — the compound in psychedelic mushrooms — and then they went home to live the rest of their lives. Five years later, most of them still describe it as one of the most meaningful experiences they've ever had. That's a striking claim, and it deserves to be examined carefully rather than just admired. The relationship between psilocybin, addiction, depression, and the kind of existential dread that comes with a cancer diagnosis is one of the more compelling threads in current psychedelic research. It also sits at the heart of why so many people are quietly looking into psychedelic retreats — not for recreation, but because they're trying to find a way out of something that talk therapy and medication haven't touched. So let's walk through what the New York University team actually found, what it means, and what it doesn't. The original trial enrolled 29 cancer patients dealing with anxiety and depression linked to their diagnosis. Roughly 40% of people with cancer experience this kind of psychological distress — the constant low hum of fear about recurrence, about pain, about death, about the people they'll leave behind. Standard antidepressants help some patients. Many others find them flat, dulling, or simply ineffective for this particular flavor of suffering. Each participant received a single dose of psilocybin in a supervised therapeutic setting, paired with psychotherapy before and after. The setting matters. This wasn't a pill handed over with a glass of water. It was hours spent lying on a couch, eye shades on, music playing, with two trained guides nearby. The session itself typically runs around six hours. The short-term results — reported in 2016 — were already remarkable. Patients showed dramatic drops in measures of anxiety and depression within weeks. What nobody knew was whether those effects would hold. In the long-term follow-up, researchers tracked down the surviving participants and asked them, in detail, how they were doing. Around 80% still reported clinically significant reductions in anxiety and depression. Most rated the psilocybin session as among the top five most meaningful experiences of their entire lives — comparable, for many, to the birth of a child or the death of a parent. Roughly 96% called it one of the most spiritually significant experiences they'd ever had. Prior to this work, the longest follow-up in any modern psychedelic trial had been twelve months. Five years is a different order of evidence. It suggests something more than a temporary mood lift. It suggests that whatever shifted in these patients had become part of how they live. One participant put it plainly: even after being diagnosed with a second, unrelated cancer years later, the dread that used to swallow her whole simply wasn't there anymore. She got the tests. She had the operations. She kept moving. The qualitative reports are where the study gets genuinely interesting. The numbers tell you something measurable shifted; the words tell you what the shift felt like from the inside. That last one is the kind of insight people spend decades in therapy trying to reach. None of this is mystical accounting. These are normal people describing what it's like to be less afraid. Researchers genuinely don't know yet, and the honest ones say so. But a few hypotheses keep showing up in the literature. One is that psilocybin temporarily quiets the default mode network — the part of the brain associated with the running narrative of self, the inner monologue, the rumination loop. When that network goes offline, the rigid sense of "I am this person with this disease and this future" loosens. Patients describe stepping outside themselves and seeing their lives from a different angle. Sometimes what they see changes them. Another idea is that psychedelics increase neural flexibility — they make the brain more receptive to new ideas, new emotional patterns, new ways of organizing memory. Robin Carhart-Harris, one of the more prominent researchers in the field, has described it as a kind of lubrication: cogs that had been stuck for years suddenly turning freely. Whether that lubrication lasts depends on what you do with it afterward, which is why integration — the unsexy work of making sense of the experience in the weeks and months that follow — gets so much attention in serious psychedelic therapy. The NYU work doesn't sit alone. Johns Hopkins has run parallel studies with similar results. Trials on psilocybin for treatment-resistant depression, on MDMA for PTSD, on ibogaine for opioid dependence, on ayahuasca for addiction and trauma — they keep producing the same shape of result. Durable effects from a small number of sessions, in carefully supported settings, when standard treatments haven't worked. This is also why master plants and synthesized psychedelics keep showing up in the same conversation. The traditions around ayahuasca, San Pedro, and psilocybin mushrooms have understood for centuries that these substances can crack open something fixed — a fear, a grief, a way of seeing yourself — and that the cracking only heals well if there's care around it. Modern clinical trials are, in a sense, rediscovering what curanderos already knew, just with statistical significance attached. The legal landscape is shifting too. Oregon and Colorado now have regulated psilocybin therapy programs. Several U.S. cities have decriminalized personal use. Australia legalized psilocybin for treatment-resistant depression under specialist prescription. None of this makes the substances casual — they remain serious — but it does mean access is broadening for the first time in half a century. If you've been reading research like the NYU study and quietly wondering whether a psilocybin retreat — or an ayahuasca ceremony, or another plant-medicine experience — might help you with something stuck in your own life, a few honest notes. The research is genuinely promising. It's also early, and the most interesting findings come from settings where care, screening, and integration were taken seriously. If reading about studies like this has stirred something in you, the next step is probably less about booking the first retreat you find and more about understanding what a well-run one actually looks like. For readers who want to take that next step thoughtfully, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you choose, choose slowly. The medicine isn't going anywhere, and the right setting is worth waiting for.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
